Women and Lung Cancer Research and Preventive Services Act of 2025
Sponsored By: Senator Smith, Tina [D-MN]
In Committee
Summary
Improve lung cancer research and screening for women and populations with few known risk factors. This bill would direct the Department of Health and Human Services, with the Departments of Defense and Veterans Affairs, to review and update federal programs, research, screening, and public outreach related to lung cancer and to report findings to Congress within 2 years.
Show full summary
- Women and low-risk populations: Would require identifying knowledge gaps and expanding research into environmental and genomic factors to better understand lung cancer causes and outcomes in these groups.
- People eligible for screening: Would aim to improve lung cancer screening rates among groups the U.S. Preventive Services Task Force recommends, and consider new public awareness and education strategies to boost early detection.
- Researchers and agencies: Would encourage interagency and multidisciplinary research, including development of biomarkers and technology to improve risk assessment, diagnosis, and treatment.
- Federal programs and policy: Would assess current federal activities and strategic plans, recommend program updates, and flag statutory or other barriers to implementing changes for congressional review.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Boost lung cancer research for women
If enacted, the bill would require the HHS Secretary to review federal lung cancer programs for research, screening, and treatment. The Secretary would consult the Defense and Veterans Affairs departments. The review would focus on lung cancer in women, populations with few known risk factors, and USPSTF-recommended screening groups. It would examine current studies, ongoing federally funded research, and knowledge gaps, including environmental and genomic factors. The review would consider interagency research, multidisciplinary projects, new technologies like biomarker testing, and public awareness strategies. Within 2 years, the Secretary would report to specified House and Senate committees with findings, any program changes, recommended changes, and barriers to implementation.
Sponsors & CoSponsors
Sponsor
Smith, Tina [D-MN]
MN • D
Cosponsors
Shelley Capito
WV • R
Sponsored 3/26/2025
Sen. Hirono, Mazie K. [D-HI]
HI • D
Sponsored 1/8/2026
Sen. Collins, Susan M. [R-ME]
ME • R
Sponsored 1/8/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov